Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.

Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in ...

Ketamine is an injectable anesthetic (a medicine that puts people to sleep during surgical procedures). Ketamine is related to the recreational drug phencyclidine (PCP). Studies have found that low ...

The diagnosis of major depressive disorder is based on the patient's self-reported experiences, behavior reported by relatives or friends, and a mental status examination. There is no laboratory ...

Background: Depressive disorders are highly prevalent, have a detrimental impact on the quality of life of patients and their relatives and are associated with increased mortality rates ...

Major Depressive Disorder, and Persistent Depressive Disorder. These reports include a comprehensive understanding of current treatment practices, emerging drugs, market share of individual ...

Ketamine can effectively treat depression, but whether depressed patients with alcohol use disorder can safely use ketamine ...

Thase, MD, professor of psychiatry at the Perelman School of Medicine at the University of Pennsylvania, discusses: The factors that can trigger major depressive disorders; Pharmacological options ...

How does uncertainty affect mental health? Political and economic instability fuel anxiety, depression, and cognitive strain.

The frequent keywords Alzheimer’s disease, dementia, and mild cognitive impairment (MCI) emphasize the research focus on the link between depression and dementia. This highlights ongoing efforts to ...